NUR 6410 Module 3 Chronic Prescribing Case: Asthma Step-Up to Budesonide-Formoterol Example

One Inhaler for Both Jobs: Stepping Up Asthma Treatment With Budesonide-Formoterol for a 27-Year-Old Medical Assistant in Newark

Student Name

Master of Science in Nursing, Thomas Edison State University

NUR-6410: Advanced Pharmacology

Mentor Name

Month Day, Year

One Inhaler for Both Jobs: Stepping Up Asthma Treatment With Budesonide-Formoterol for a 27-Year-Old Medical Assistant in Newark

Introduction

Ms. M. is an invented patient, a 27-year-old medical assistant of Puerto Rican heritage who works at a busy pediatric practice in Newark. She was diagnosed with asthma as a child and has used only an albuterol inhaler since her teens. Since July she has reached for it four days in a typical week, usually after the station stairs or after spraying disinfectant in exam rooms. Twice a month she wakes at night with a tight chest and coughs until she uses her inhaler. She missed two days of work last winter with a chest cold that settled in her lungs. She has never been prescribed a controller and is worried about steroids because her mother gained weight on prednisone.

Classifying Control

Asthma control is judged by daytime symptoms, night waking, reliever use, interference with activity and exacerbations. Using a reliever more than two days a week and waking at night once or twice a month places her asthma above the well-controlled range, and her missed work days suggest risk of exacerbation as well. Her treatment needs to step up. Severity and control are different questions: severity describes how much treatment a person needs to stay well, while control describes how well the current plan is working. Because she has never had a controller, her current pattern reflects untreated asthma, and the guideline step chosen for her is set by how she is doing now rather than by a label from childhood. Her exacerbation last winter matters too, since a recent attack is one of the strongest predictors of the next one.

Why Albuterol Alone Is Not Enough

Albuterol relaxes airway smooth muscle within minutes but does nothing about the inflammation that makes her airways twitchy. Each puff gives relief and hides the underlying process, and patients who rely on short-acting bronchodilators alone are at greater risk of severe attacks. This is the reasoning behind a shift in asthma care over the past decade: the reliever itself should carry an anti-inflammatory dose, so that every time she treats symptoms she also treats inflammation.

The Evidence for Combined Inhalers

O'Byrne et al. (2018) tested as-needed budesonide-formoterol in mild asthma in the SYGMA 1 trial. Compared with as-needed terbutaline alone, it improved symptom control and reduced severe exacerbations. Compared with daily budesonide plus terbutaline as needed, it gave somewhat less symptom control but a similar rate of severe exacerbations, with a much lower total steroid dose because patients used it only when they needed relief. Sobieraj et al. (2018) pooled trials of single maintenance and reliever therapy, in which the same inhaler of an inhaled corticosteroid with formoterol is used daily and for relief. Across their analysis, that approach reduced the risk of exacerbations compared with a controller inhaler plus a separate short-acting reliever.

Formoterol can be used as a reliever because, unlike other long-acting beta agonists, it begins to work within minutes. Salmeterol does not, so the same approach cannot be used with salmeterol combinations.

Applying the 2020 Guideline

The 2020 NAEPP expert panel update (Cloutier et al., 2020) names a single inhaler of an inhaled corticosteroid with formoterol, used daily and as needed, as the preferred choice at steps 3 and 4 for anyone 12 or older. Ms. M.'s level of symptoms and night waking fits step 3, where the guideline uses low-dose inhaled corticosteroid with formoterol. In the United States the available product is budesonide-formoterol 80/4.5 micrograms per inhalation.

Her script: budesonide-formoterol 80/4.5, two puffs morning and evening, plus one or two extra puffs when she feels tight, never more than a dozen puffs across a whole day. Her albuterol is stopped as her routine reliever, though she may keep one as a backup until she is confident with the new plan. A spacer is not needed for this metered-dose inhaler if her technique is good, but it is a reasonable addition if she struggles to coordinate breathing and pressing.

Adverse Effects and Concerns

Her fear of steroids deserves a direct answer. Inhaled budesonide at this dose delivers a small fraction of the steroid in prednisone, and most of it acts in the airways. The common local effects are oral thrush and a hoarse voice, both reduced by rinsing and spitting after each use. Formoterol can cause a fast heartbeat or tremor at higher doses. Systemic steroid effects such as weight gain are unlikely at low inhaled doses. Explaining the difference between inhaled and oral steroids and showing her the dose numbers often changes how patients feel about their controller.

Triggers, Work and Culture

Her job exposes her to disinfectant sprays, which can trigger asthma in health care workers. Asking her employer for wipes rather than sprays, or for better ventilation, is a reasonable step. Puerto Rican adults have among the highest asthma rates of any group in the United States, and Ms. M.'s family history and urban environment add to her risk. A culturally responsive plan uses her preferred language for teaching materials, involves family members she relies on and acknowledges her mother's experience with prednisone without dismissing it. Cost matters too: brand budesonide-formoterol can be expensive, and checking her insurance formulary, generic availability or patient assistance programs before she leaves the clinic prevents an unfilled prescription.

Monitoring and Follow-Up

She returns in four to six weeks. At that visit the prescriber checks inhaler technique, symptom frequency, night waking, how many as-needed inhalations she uses a week and any exacerbations. A validated control questionnaire gives a number to follow over time. Spirometry, if not done recently, helps confirm the diagnosis and her baseline. If she is well controlled for three months, stepping down can be considered. If she remains poorly controlled, adherence and technique are checked before the dose is increased.

Conclusion

Ms. M.'s asthma is not well controlled on albuterol alone, which treats symptoms and leaves inflammation untouched. Guided by the 2020 update, SYGMA 1 and the pooled trials of one-inhaler regimens, she now uses budesonide-formoterol both on schedule and for flares. The plan addresses her fear of steroids, her workplace triggers, her cost and her follow-up.

References

Cloutier, M. M., Baptist, A. P., Blake, K. V., Brooks, E. G., Bryant-Stephens, T., DiMango, E., Dixon, A. E., Elward, K. S., Hartert, T., Krishnan, J. A., Lemanske, R. F., Ouellette, D. R., Pace, W. D., Schatz, M., Skolnik, N. S., Stout, J. W., Teach, S. J., Umscheid, C. A., & Walsh, C. G. (2020). 2020 focused updates to the asthma management guidelines: A report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. Journal of Allergy and Clinical Immunology, 146(6), 1217-1270. https://doi.org/10.1016/j.jaci.2020.10.003

O'Byrne, P. M., FitzGerald, J. M., Bateman, E. D., Barnes, P. J., Zhong, N., Keen, C., Jorup, C., Lamarca, R., Ivanov, S., & Reddel, H. K. (2018). Inhaled combined budesonide-formoterol as needed in mild asthma. New England Journal of Medicine, 378(20), 1865-1876. https://doi.org/10.1056/NEJMoa1715274

Sobieraj, D. M., Weeda, E. R., Nguyen, E., Coleman, C. I., White, C. M., Lazarus, S. C., Blake, K. V., Lang, J. E., & Baker, W. L. (2018). Association of inhaled corticosteroids and long-acting beta-agonists as controller and quick relief therapy with exacerbations and symptom control in persistent asthma: A systematic review and meta-analysis. JAMA, 319(14), 1485-1496. https://doi.org/10.1001/jama.2018.2769